Flex Pharma Inc Stock Nasdaq
Equities
US33938A1051
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.13M |
---|---|---|---|---|---|
Net income 2024 * | -21M | Net income 2025 * | -23M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.02
x | P/E ratio 2025 * |
-0.02
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.27% |
Managers | Title | Age | Since |
---|---|---|---|
David Arthur
CEO | Chief Executive Officer | 61 | 19-07-18 |
Mark Rosenblum
DFI | Director of Finance/CFO | 70 | 19-09-09 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19-07-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 19-07-18 |
Paul Lammers
BRD | Director/Board Member | 66 | 19-07-18 |
Jonathan Lieber
BRD | Director/Board Member | 54 | 20-06-18 |
1st Jan change | Capi. | |
---|---|---|
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
-4.07% | 11.68B | |
+21.36% | 11.6B | |
+8.20% | 11.15B |